Johnson & Johnson Announces Two-year Data From Its Phase 3 ICONIC-TOTAL Study Of ICOTYDE On High-Impact Plaque Psoriasis Sites; 60% Of Patients With Scalp Psoriasis And 89% With Genital Psoriasis Achieved Site-Specific Complete Skin Clearance At Week 112
Key takeaways
- ICOTYDE shows durable, high‑impact psoriasis clearance over two years, reinforcing its therapeutic value and market position.
- Overall IGA 0/1: 70% at week 112
- Scalp ss‑IGA 0: 60% at week 112
- Genital sPGA‑G 0: 89% at week 112
What happened
Johnson & Johnson’s psoriasis drug ICOTYDE delivered two‑year data at the European Academy of Dermatology and Venereology Congress, showing sustained skin clearance in high‑impact sites. Across 112 weeks, overall clear or almost clear skin rose from 57% at week 16 to 70% at week 112. Site‑specific results were striking: 60% of scalp psoriasis patients achieved complete scalp clearance, 89% of genital psoriasis patients reached full genital clearance, and 63% of hand/foot psoriasis patients…
Why it matters
These long‑term results confirm ICOTYDE’s durability and effectiveness in the most disabling psoriasis sites, which are often refractory to topical treatments. High clearance rates in scalp, genital, and hand/foot areas translate to significant quality‑of‑life gains for patients. The data strengthen the drug’s…
Short-term and longer-term
Short-term. Short‑term traders should note that the two‑year data may prompt a rally in JNJ shares as the drug’s durability is confirmed.
Longer-term. Long‑term investors view ICOTYDE’s sustained efficacy as a key driver for future revenue growth in the dermatology segment.